(Q37500031)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19479263%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

review article

1 reference

title

Combination of BCG and interferon intravesical immunotherapy: an update (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19479263%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19479263%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

M A O'Donnell

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19479263%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Howard A Aubert

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19479263%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Matthew R Braasch

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19479263%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

language of work or name

1 reference

29 May 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19479263%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

published in

World Journal of Urology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19479263%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19479263%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

343-346

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19479263%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19479263%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00345-009-0429-6

29 January 2020

exact match

0 references

cites work

Role of neutrophils in BCG immunotherapy for bladder cancer

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00345-009-0429-6

Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy

21 January 2018

1 reference

12 December 2020

Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer

1 reference

12 December 2020

Second-line intravesical therapy versus cystectomy for bacille Calmette-Guérin (BCG) failures

1 reference

12 December 2020

Treatment of residual, non-infiltrating bladder cancer with bacillus Calmette-Guerin

1 reference

12 December 2020

The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy

1 reference

12 December 2020

Maintenance Bacillus Calmette-Guerin for Ta T1 Bladder Tumors Is Not Associated with Increased Toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial

1 reference

12 December 2020

Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

1 reference

12 December 2020

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update

1 reference

12 December 2020

Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs

1 reference

12 December 2020

IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy.

1 reference

12 December 2020

Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy

1 reference

12 December 2020

Superficial bladder cancer: the role of interferon-alpha.

1 reference

12 December 2020

Treatment options for BCG failures.

1 reference

12 December 2020

Treatment of BCG failures with intravesical BCG/Interferon: the University of Montreal experience

1 reference

12 December 2020

Interferons and bladder cancer

1 reference

12 December 2020

Antiproliferative effects of bacillus Calmette-Gu�rin and interferon ?2b on human bladder cancer cells in vitro

1 reference

12 December 2020

Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

1 reference

12 December 2020

A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder

1 reference

12 December 2020

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder

1 reference

12 December 2020

Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer

1 reference

12 December 2020

Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy.

1 reference

12 December 2020

Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed

1 reference

12 December 2020

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors

1 reference

12 December 2020

Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.

1 reference

12 December 2020

Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity

1 reference

12 December 2020

10.1007/S00345-009-0429-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19479263%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference